Free Trial
NASDAQ:ARVN

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas logo
$7.79 -0.10 (-1.27%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$7.78 0.00 (-0.06%)
As of 07/11/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arvinas Stock (NASDAQ:ARVN)

Key Stats

Today's Range
$7.70
$7.95
50-Day Range
$6.07
$8.23
52-Week Range
$5.90
$34.11
Volume
1.28 million shs
Average Volume
1.49 million shs
Market Capitalization
$568.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.29
Consensus Rating
Moderate Buy

Company Overview

Arvinas Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

ARVN MarketRank™: 

Arvinas scored higher than 79% of companies evaluated by MarketBeat, and ranked 310th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 12 buy ratings, 10 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arvinas has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arvinas' stock forecast and price target.
  • Earnings Growth

    Earnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arvinas is -11.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arvinas is -11.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arvinas has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Arvinas' valuation and earnings.
  • Percentage of Shares Shorted

    10.28% of the float of Arvinas has been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently decreased by 14.17%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Arvinas does not currently pay a dividend.

  • Dividend Growth

    Arvinas does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.28% of the float of Arvinas has been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently decreased by 14.17%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Arvinas has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Arvinas this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,377.00 in company stock.

  • Percentage Held by Insiders

    Only 4.73% of the stock of Arvinas is held by insiders.

  • Percentage Held by Institutions

    95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arvinas' insider trading history.
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Arvinas: John Houston to Retire as President, CEO
See More Headlines

ARVN Stock Analysis - Frequently Asked Questions

Arvinas' stock was trading at $19.17 at the beginning of the year. Since then, ARVN shares have decreased by 59.4% and is now trading at $7.79.

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Thursday, May, 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $2.07. The business's revenue was up 646.2% on a year-over-year basis.
Read the conference call transcript
.

Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas' top institutional shareholders include Assenagon Asset Management S.A. (0.07%). Insiders that own company stock include John G Houston, Sean A Cassidy, Andrew Saik, Ian Taylor, Noah Berkowitz, Ronald Peck and David K Loomis.
View institutional ownership trends
.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/01/2025
Today
7/13/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARVN
CIK
1655759
Fax
N/A
Employees
420
Year Founded
N/A

Price Target and Rating

High Price Target
$55.00
Low Price Target
$8.00
Potential Upside/Downside
+160.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
22 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$198.90 million
Net Margins
-10.92%
Pretax Margin
-10.75%
Return on Equity
-7.74%
Return on Assets
-4.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.58
Quick Ratio
4.58

Sales & Book Value

Annual Sales
$263.40 million
Price / Sales
2.16
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.17 per share
Price / Book
0.95

Miscellaneous

Outstanding Shares
72,990,000
Free Float
69,539,000
Market Cap
$568.59 million
Optionable
Optionable
Beta
2.17
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ARVN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners